QR code

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

ObjectiveTo investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).MethodsReports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004–2023q3) were identified. Demographic and clinical characteristics...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Shuang Xia, Jing-Wen Xu, Kang-Xin Yan, Yoshihiro Noguchi, Mayur Sarangdhar, Miao Yan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2024-09-01
Reeks:Frontiers in Pharmacology
Onderwerpen:
encorafenib
binimetinib
tumor lysis syndrome
malignant melanoma
pharmacovigilance
FAERS
Online toegang:https://www.frontiersin.org/articles/10.3389/fphar.2024.1413154/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items